FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

-t D.C. 20E40	
gton, D.C. 20549	OMB APPROV
	OIVID APPROVI

UNID APP	ROVAL
OMB Number:	3235-0287

0.5

Estimated average burden

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ARROWHEAD RESEARCH CORP [ARWR									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Anzalone Christopher Richard					ARWIC							X	Director		10% Owner		ner		
(Last)	(First) (Middle)					,							X	Officer (give title below)			Other (s below)	pecify	
225 SOUTH LAKE AVENUE, SUITE 1050					3. Date of Earliest Transaction (Month/Day/Year) 03/04/2015								President and CEO						
(Street) PASADENA CA 91101					4. If Amendment, Date of Original Filed (Month/Day/Year)							1	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(City)	(5	State)	(Zip)		Form filed by More than One Rep								One Reporti	ng Person					
		7	Γable I - Non-Γ	eriva	tive S	Securities	s Ac	quired, I	Dis	oosed of,	or Be	nefi	cially (Owned					
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I				ite		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed C		es Acquired (A) or Of (D) (Instr. 3, 4 a			nd 5) Securities Beneficial Owned Fo		6. Own Form: (D) or I (I) (Inst	Direct I Indirect I tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) (D)	or	Price	Reported Transactio (Instr. 3 an				1501. 4)	
Common Stock (3/04/2015				A		360,000	1)	1	\$0	620,173			D			
			Table II - De					,	•	osed of, o			•	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amof Securities Underlying Derivative Securities (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e Own s Forn lily Dire or In g (I) (II	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	OI N	mount r umber f Shares		(Instr. 4)				
Stock	¢7.75	03/06/2015		Λ		200 000(2)		(3)		2/06/2025(4)	Comm	on 3	00 000	¢0	1.096	466	D		

Explanation of Responses:

- 1. Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of certain predetermined performance goals related to the advancement of the Company's clinical programs and business development over three to five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
- 2. Represents the maximum number of shares issuable pursuant to the stock option grant that vest based on the achievement of certain predetermined goals related to the advancement of the Company's clinical programs and business development over three to five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
- 3. Vests and become exercisable over a three to five year period if performance goals are met.
- 4. Stock option has a maximum ten year term, but may expire earlier if performance goals are not met.

Christopher R. Anzalone 03/06/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.